Effect of vascular endothelial growth factor inhibitors on choroid in patients with macular choroid neovascular membrane and degenerative myopia . Preliminary report

Purpose: to assess the effect of vascular endothelial growth factor inhibitors on choroid in patients with myopic macular choroid neovascular membrane.
Methods: 12 eyes (12 patients) aged 19-47 years with myopia and macular choroid neovascular membrane (mCNV) were enrolled in a study group. A control group included fellow eyes with early «dry» form age-related macular degeneration. Eyes with mCNV under- went one intravitreal injection of vascular endothelial growth factor inhibitor Ranibizumab 0.5 mg. Retina and choroid examination was performed with SPECtRALIS HRA+OCt (Heidelberg Engineering). Eyes were examined before treatment, in 1 month and in 3 months after treatment.
Results: Mean best corrected visual acuity in 1 moth after ranibizumab 0.5 mg injection improved from 0.37±0.18 to 0.47±0.24. In 3 months after treatment best corrected visual acuity was 0.53±0.24. Mean foveal retinal thickness before treatment was 311.4±57.2 μm; 1 month and 3 months after treatment mean foveal retinal thickness decreased to 229.1±41.8 μm and 221.8±29.3 μm, respec- tively. Mean choroid thickness in 1 moth decreased from 54.4±23.7 μm to 37.4±17.0 μm, in 3 moths mean choroid thickness was 48.9±20.1 μm. In the control group best corrected visual acuity was 0.79±0.18, mean foveal retinal thickness and mean choroid thick- ness were 187.1±10.5 μm and 93.7±24.5 μm, respectively.
Conclusion: Injection of vascular endothelial growth factor inhibitor allowed transient choroid thinning.

1. Измайлов А. С., Балашевич Л. И. Хориоидальная неоваскуляризация (диагно‐ стика и лечение). Учебное пособие — СПб., 2001.

2. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2‐year results of a random‐ ized clinical trial — VIP report no 3 // Ophthalmology. — 2003. — Vol. 110. — P. 667‐673.

3. Gharbiya M, Allievi F, Mazzeo L, et al. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12‐month results // Am J Ophthalmol. — 2009. — Vol. 147. — P. 84‐93.

4. Inan U. U., Avei В., Kusbeci Т. Preclinical safety evaluation of intravitreal injec‐ tion of full‐ length humanized vascular endothelial growth factor antibody in rat eyes // Invest. Ophthalmol. Vis. Sci. — 2007. — Vol. 48. — P. 1773‐1781.

5. Manzano RP, Peyman GA, Khan P, et al. Testing intravitreal toxicity of bevaci‐ zumab (Avastin) // Retina. — 2006. — Vol. 26. — P. 257‐261.

6. Marneros A. G., Fan J., Yokoyama Y., et al. Vascular endothelial growth factor ex‐ pression in retinal pigment epithelium is essential for choriocapillaris develop‐ ment and vision function // Am. J. Pathol. — 2005. — Vol. 167. — P. 1451‐1459.

7. Fujiwara T, Imamura Y, Margolis R, et al. Enhanced depth imaging optical coher‐ ence tomography of the choroid in highly myopic eyes // Am J Ophthalmol. — 2009. — Vol. 148. — P. 445‐450.

8. Ikuno Y, Tano Y. Retinal and choroidal biometry in highly myopic eyes with spec‐ tral‐domain optical coherence tomography // Invest Ophthalmol Vis Sci. — 2009. — Vol. 50. — P. 3876‐3880.

9. Margolis R, Spaide RF. A pilot study of enhanced depth imaging optical coher‐ ence tomography of the choroid in normal eyes // Am J Ophthalmol. — 2009. — Vol. 147. — P. 811‐815.